RCZY-869 / Rongchang Pharma - LARVOL DELTA

RCZY-869: A highly potent, selective, and orally bioavailable covalent KRASG12D (ON-state) inhibitor with robust antitumor activity in preclinical models of KRASG12D-driven solid tumors (AACR 2026) - "Phase 1/1b data show ON-state inhibitor RMC-9805 and ON/OFF inhibitor VS-7375 (GFH375) have comparable objective response rates (ORR) and disease control rates (DCR) in NSCLC at their respective recommended Phase 2 doses (RP2D). These findings position RCZY-869 as a novel ON-state-selective KRASG12D inhibitor with compelling preclinical potency and efficacy. Ongoing characterization advances its candidate package to support clinical development."

Preclinical • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS